European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Core Points - Halozyme Therapeutics announced the European Commission's marketing authorization for the subcutaneous formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for first-line treatment of advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] - The approval also includes amivantamab as a monotherapy for advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy [1] - The subcutaneous formulation utilizes Halozyme's ENHANZE® drug delivery technology, which aims to improve patient experience by reducing administration time and infusion-related reactions [2][3] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes, particularly through its ENHANZE® drug delivery technology [4] - The company has successfully licensed its ENHANZE® technology to major pharmaceutical companies, impacting over one million patients globally [4] - Halozyme also develops drug-device combination products aimed at improving convenience, reliability, and patient adherence [5]